Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme

Anticancer Research

Volumn 37, Issue 1, 2017, Pages 21-33

  Polivka, Jiri ^a   Holubec, Lubos ^a   Kubikova, Tereza ^a   Priban, Vladimir ^a   Hes, Ondrej ^a   Pivovarcikova, Kristyna ^a   Treskova, Inka ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Clinical trials; CTLA4 inhibition; GBM; Glioblastoma multiforme; Immune checkpoint inhibitors; Immunotherapy; PD1 inhibition; Personalized medicine; Review; Targeted therapy

Indexed keywords

AFATINIB; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CANCER VACCINE; CEDIRANIB; CETUXIMAB; CHECKPOINT KINASE INHIBITOR; CILENGITIDE; DASATINIB; DENDRITIC CELL VACCINE; ERLOTINIB; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMATINIB; IRINOTECAN; LAPATINIB; LOMUSTINE; MONOCLONAL ANTIBODY; NINTEDANIB; PEMBROLIZUMAB; PEPTIDE VACCINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RINDOPEPIMUT; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNINDEXED DRUG; VANDETANIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR RECURRENCE; UNITED STATES; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRENDS; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 85007580039     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11285     Document Type: Review

References (139)

1. Dolecek TA, Propp JM, Stroup NE and Kruchko C: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncol 14(Suppl 5): v1-49, 2012.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 114: 97-109, 2007.
3. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncol 16(Suppl 4): iv1-63, 2014.
4. Polivka J Jr, Polivka J, Rohan V, Topolcan O and Ferda J: New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res 32: 2935-2946, 2012.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
6. Tosoni A, Franceschi E, Poggi R and Brandes AA: Relapsed glioblastoma: treatment strategies for initial and subsequent recurrences. Curr Treat Options Oncol 17: 49, 2016.
7. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G and German Glioma Network: Longterm survival with glioblastoma multiforme. Brain J Neurol 130: 2596-2606, 2007.
8. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
9. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I-M, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE and Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
10. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006.
11. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Tirapelli DP da C, Rao A, Mikkelsen T, Lau CC, Yung WKA, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network, Noushmehr H, Iavarone A and Verhaak RGW: Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164: 550-563, 2016.
12. Polivka J, Polivka J, Repik T, Rohan V, Hes O and Topolcan O: Co-deletion of 1p/19q as prognostic and predictive biomarker for patients in West Bohemia with anaplastic oligodendroglioma. Anticancer Res 36: 471-476, 2016.
13. Xia L, Wu B, Fu Z, Feng F, Qiao E, Li Q, Sun C and Ge M: Prognostic role of IDH mutations in gliomas: A meta-analysis of 55 observational studies. Oncotarget 6: 17354-17365, 2015.
14. Polivka J, Polivka J Jr, Rohan V, Pesta M, Repik T, Pitule P and Topolcan O: Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in west bohemia. BioMed Res Int 2014: 735659, 2014.
15. Polivka J, Polivka J Jr, Rohan V and Topolcan O: Glioblastoma multiforme-A review of pathogenesis, biomarkers and therapeutic perspectives. Cesk Slov Neurol N 76/109: 575-583, 2013.
16. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol (Berl) 131: 803-820, 2016.
17. Polivka J, Polivka J, Rohan V and Topolcan O: New treatment paradigm for patients with anaplastic oligodendroglial tumors. Anticancer Res 34: 1587-1594, 2014.
18. Polivka J, Krakorova K, Peterka M and Topolcan O: Current status of biomarker research in neurology. EPMA J 7: 14, 2016.
19. Popescu AM, Purcaru SO, Alexandru O and Dricu A: New perspectives in glioblastoma antiangiogenic therapy. Contemp Oncol Pozn Pol 20: 109-118, 2016.
20. Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR and Castro MG: Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther: 1-20, 2016.
21. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
22. Polivka J and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142: 164-175, 2014.
23. Chen R, Cohen AL and Colman H: Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr Treat Options Oncol 17: 42, 2016.
24. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS and Costello JF: Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343: 189-193, 2014.
25. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ and Louis DN: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res Off J Am Assoc Cancer Res 13: 2038-2045, 2007.
26. Polivka J, Pesta M and Janku F: Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: Are we there yet? Expert Rev Mol Diagn 15: 1631-1644, 2015.
27. Rao SK, Edwards J, Joshi AD, Siu I-M and Riggins GJ: A survey of glioblastoma genomic amplifications and deletions. J Neurooncol 96: 169-179, 2010.
28. Ke E-E and Wu Y-L: EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: Where do we stand now? Trends Pharmacol Sci 37: 887-903, 2016.
29. Sacco AG and Worden FP: Molecularly targeted therapy for the treatment of head and neck cancer: A review of the ERBB family inhibitors. OncoTargets Ther 9: 1927-1943, 2016.
30. Zaniboni A and Formica V: The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemother Pharmacol, 2016.
31. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD and Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 22: 133-142, 2004.
32. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crinò L and Brandes AA: Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96: 1047-1051, 2007.
33. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E and Abrey LE: A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92: 99-105, 2009.
34. Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Clifton-Hadley L, Wanek K, Krell D, Jeffries S, Khan I, Smith P and Mulholland P: Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. PloS One 11: e0156369, 2016.
35. Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA and New Approaches to Brain Tumor Therapy Consortium: NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-Oncol 15: 490-496, 2013.
36. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MCM, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain J-F, Armand J-P, Taphoorn MJB, Tosoni A, Kletzl H, Klughammer B, Lacombe D and Gorlia T: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol Off J Am Soc Clin Oncol 27: 1268-1274, 2009.
37. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH and Friedman HS: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96: 219-230, 2010.
38. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L and Eisenhauer E: A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65: 353-361, 2010.
39. Karavasilis V, Kotoula V, Pentheroudakis G, Televantou D, Lambaki S, Chrisafi S, Bobos M and Fountzilas G: A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. J Neurol 260: 1469-1480, 2013.
40. Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM and de Bono J: A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res Off J Am Assoc Cancer Res 19: 900-908, 2013.
41. Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD and BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium: Phase I/randomized phase II study of afatinib, an irreversible ERBB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncol 17: 430-439, 2015.
42. Belda-Iniesta C, Carpeño J de C, Saenz EC, Gutiérrez M, Perona R and Barón MG: Long-term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther 5: 912-914, 2006.
43. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen M-T and Poulsen HS: Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial. Neuro-Oncol 12: 508-516, 2010.
44. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JHY, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL and Mischel PS: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024, 2005.
45. Wachsberger PR, Lawrence RY, Liu Y, Rice B, Daskalakis C and Dicker AP: Epidermal growth factor receptor mutation status and RAD51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation. Front Oncol 3: 13, 2013.
46. Gajadhar AS, Bogdanovic E, Muñoz DM and Guha A: In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol Cancer Res MCR 10: 428-440, 2012.
47. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN and Cancer Genome Atlas Research Network: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110, 2010.
48. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von Deimling A and Nistér M: Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56: 164-171, 1996.
49. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15: 275-286, 2004.
50. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PMJ, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ and European Organisation for Research and Treatment of Cancer Brain Tumor Group Study: Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol Off J Am Soc Clin Oncol 26: 4659-4665, 2008.
51. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A and Nikolova Z: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101: 1995-2004, 2009.
52. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R and Nikolova Z: Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96: 393-402, 2010.
53. Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL and Lamar RE: Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116: 3663-3669, 2010.
54. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE and Wen PY: Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78: 85-90, 2010.
55. Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL and Wen PY: A Multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res Off J Am Assoc Cancer Res 21: 3610-3618, 2015.
56. Muhic A, Poulsen HS, Sorensen M, Grunnet K and Lassen U: Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol 111: 205-212, 2013.
57. Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA and Wen PY: Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol 121: 297-302, 2015.
58. Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, Youssef E, Wagner H, Won M and Mehta MP: Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncol 17: 992-998, 2015.
59. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amistà P, Rotilio A, Licata C and Fiorentino MV: Procarbazine and highdose tamoxifen as a second-line regimen in recurrent highgrade gliomas: A phase II study. J Clin Oncol Off J Am Soc Clin Oncol 17: 645-650, 1999.
60. Spence AM, Peterson RA, Scharnhorst JD, Silbergeld DL and Rostomily RC: Phase II study of concurrent continuous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol 70: 91-95, 2004.
61. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE and Fine HA: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 28: 1168-1174, 2010.
62. Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D and Fine HA: A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncol 12: 181-189, 2010.
63. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted therapy for malignant glioma. Cancer 110: 13-24, 2007.
64. Akhavan D, Cloughesy TF and Mischel PS: mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncol 12: 882-889, 2010.
65. Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC and Sarkaria JN: A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncol 17: 1261-1269, 2015.
66. Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF and Mason WP: Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncol 17: 1270-1274, 2015.
67. Bai R-Y, Staedtke V and Riggins GJ: Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med 17: 301-312, 2011.
68. Majuelos-Melguizo J, Rodríguez MI, López-Jiménez L, Rodríguez-Vargas JM, Martí Martín-Consuegra JM, Serrano-Sáenz S, Gavard J, de Almodóvar JMR and Oliver FJ: PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma. Oncotarget 6: 4790-4803, 2015.
69. Gray GK, McFarland BC, Nozell SE and Benveniste EN: NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother 14: 1293-1306, 2014.
70. Hui L and Chen Y: Tumor microenvironment: Sanctuary of the devil. Cancer Lett 368: 7-13, 2015.
71. Khasraw M, Ameratunga MS, Grant R, Wheeler H and Pavlakis N: Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev: CD008218, 2014.
72. Norden AD, Drappatz J and Wen PY: Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7: 1152-1160, 2008.
73. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, Broggi G and Boiardi A: Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62: 297-303, 2003.
74. Nam D-H, Park K, Suh YL and Kim J-H: Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 11: 863-869, 2004.
75. Beal K, Abrey LE and Gutin PH: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol Lond Engl 6: 2, 2011.
76. Sica G, Lama G, Anile C, Geloso MC, La Torre G, De Bonis P, Maira G, Lauriola L, Jhanwar-Uniyal M and Mangiola A: Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int J Oncol 38: 41-49, 2011.
77. Afshar Moghaddam N, Mahsuni P and Taheri D: Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma. Iran J Pathol 10: 89-96, 2015.
78. Curry RC, Dahiya S, Alva Venur V, Raizer JJ and Ahluwalia MS: Bevacizumab in high-grade gliomas: past, present, and future. Expert Rev Anticancer Ther 15: 387-397, 2015.
79. Fu P, He Y-S, Huang Q, Ding T, Cen Y-C, Zhao H-Y and Wei X: Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. Mol Clin Oncol 4: 833-838, 2016.
80. Ghiaseddin A and Peters KB: Use of bevacizumab in recurrent glioblastoma. CNS Oncol 4: 157-169, 2015.
81. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol Off J Am Soc Clin Oncol 25: 4722-4729, 2007.
82. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M and Lassen U: Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol Stockh Swed 48: 52-58, 2009.
83. Verhoeff JJC, Lavini C, van Linde ME, Stalpers LJA, Majoie CBLM, Reijneveld JC, van Furth WR and Richel DJ: Bevacizumab and dose-intense temozolomide in recurrent highgrade glioma. Ann Oncol Off J Eur Soc Med Oncol ESMO 21: 1723-1727, 2010.
84. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27: 4733-4740, 2009.
85. Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ, Buter J, Honkoop AH, Boerman D, de Vos FYF, Dinjens WNM, Enting RH, Taphoorn MJB, van den Berkmortel FWPJ, Jansen RLH, Brandsma D, Bromberg JEC, van Heuvel I, Vernhout RM, van der Holt B and van den Bent MJ: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncol 15: 943-953, 2014.
86. Wick W, Brandes AA, Gorlia T, Bendszus M, Sahm F, Taal W, Taphoorn MJB, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Rhun EL, Dubois F, Klein M, Platten M, Weller M, Golfinopoulos V and Bent MJVD: EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. J Clin Oncol 34, 2016.
87. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD and Friedman HS: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res Off J Am Assoc Cancer Res 17: 4119-4124, 2011.
88. Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT and Spigel DR: Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol HO 10: 240-246, 2012.
89. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R and Cloughesy T: Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol Off J Am Soc Clin Oncol 29: 142-148, 2011.
90. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ and Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370: 699-708, 2014.
91. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2014.
92. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS and Bais C: Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol Off J Am Soc Clin Oncol 33: 2735-2744, 2015.
93. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY and Jain RK: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 28: 2817-2823, 2010.
94. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q and van den Bent M: Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 31: 3212-3218, 2013.
95. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M and Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycineaspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol Off J Am Soc Clin Oncol 26: 5610-5617, 2008.
96. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam D-H, Hau P, Weyerbrock A, Taphoorn MJB, Shen C-C, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann R-D, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim C-Y, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M, European Organisation for Research and Treatment of Cancer (EORTC), Canadian Brain Tumor Consortium and CENTRIC study team: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15: 1100-1108, 2014.
97. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WKA, Chen A, Prados MD and Wen PY: Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol Off J Am Soc Clin Oncol 29: 2689-2695, 2011.
98. Curtis SA, Cohen JV and Kluger HM: Evolving immuno-therapy approaches for renal cell carcinoma. Curr Oncol Rep 18: 57, 2016.
99. Khanna P, Blais N, Gaudreau P-O and Corrales-Rodriguez L: Immunotherapy comes of age in lung cancer. Clin Lung Cancer, 2016.
100. Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A and Chamie K: Immunotherapy in the treatment of urothelial carcinoma. J Urol, 2016.
101. Margolin K: The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr Treat Options Oncol 17: 48, 2016.
102. Fecci PE, Heimberger AB and Sampson JH: Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res Off J Am Assoc Cancer Res 20: 5620-5629, 2014.
103. Weathers S-P and Gilbert MR: Current challenges in designing GBM trials for immunotherapy. J Neurooncol 123: 331-337, 2015.
104. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WKA, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, Buckner JC, James CD and Aldape K: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 25: 2288-2294, 2007.
105. Gan HK, Kaye AH and Luwor RB: The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci Off J Neurosurg Soc Australas 16: 748-754, 2009.
106. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD and Heimberger AB: Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncol 13: 324-333, 2011.
107. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB and Sampson JH: A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study. Neuro-Oncol 17: 854-861, 2015.
108. Zussman BM and Engh JA: Outcomes of the ACT III study: Rindopepimut (CDX-110) therapy for glioblastoma. Neurosurgery 76: N17, 2015.
109. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S-I, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine T: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108: 963-971, 2008.
110. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN and Parsa AT: Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial. Neuro-Oncol 16: 274-279, 2014.
111. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF and Liau LM: Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 17: 1603-1615, 2011.
112. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL and Yu JS: Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother CII 62: 125-135, 2013.
113. Yang L, Guo G, Niu X and Liu J: Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. BioMed Res Int 2015: 717530, 2015.
114. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM and Prins RM: Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T-cells, before and after DC vaccination, can predict survival in GBM patients. PloS One 7: e32614, 2012.
115. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JEA, Wagner S, Kaempgen E and Van Gool SW: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res Off J Am Assoc Cancer Res 14: 3098-3104, 2008.
116. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, Demaerel P, Bijttebier P, Claes L, Goffin J, Van Calenbergh F and De Vleeschouwer S: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study. J Neurooncol 99: 261-272, 2010.
117. Hdeib A and Sloan AE: Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. CNS Oncol 4: 63-69, 2015.
118. Polyzoidis S and Ashkan K: DCVax®-L-developed by Northwest Biotherapeutics. Hum Vaccines Immunother 10: 3139-3145, 2014.
119. Schoppy DW and Sunwoo JB: Immunotherapy for head and neck squamous cell carcinoma. Hematol Oncol Clin North Am 29: 1033-1043, 2015.
120. Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, Fiorentino M, Tortora G and Massari F: Immune checkpoint inhibitors and prostate cancer: A new frontier? Oncol Rev 10: 293, 2016.
121. Mittica G, Genta S, Aglietta M and Valabrega G: Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer? Int J Mol Sci 17, 2016.
122. Preusser M, Lim M, Hafler DA, Reardon DA and Sampson JH: Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 11: 504-514, 2015.
123. Carter T, Shaw H, Cohn-Brown D, Chester K and Mulholland P: Ipilimumab and bevacizumab in glioblastoma. Clin Oncol R Coll Radiol G B, 2016.
124. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD and Sampson JH: Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T-cell compartment without affecting regulatory T-cell function. Clin Cancer Res Off J Am Assoc Cancer Res 13: 2158-2167, 2007.
125. Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M and Becher B: Intratumoral IL-12 combined with CTLA-4 blockade elicits T-cell-mediated glioma rejection. J Exp Med 210: 2803-2811, 2013.
126. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, Han Y and Lesniak MS: Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res Off J Am Assoc Cancer Res 20: 5290-5301, 2014.
127. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G and Freeman GJ: Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 4: 124-135, 2016.
128. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN and Hodi FS: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13: 459-465, 2012.
129. Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G and Maio M: Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol Off J Eur Soc Med Oncol ESMO 26: 798-803, 2015.
130. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V and Kluger HM: Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17: 976-983, 2016.
131. Rosell R and Karachaliou N: Trends in immunotherapy for brain metastases. Lancet Oncol 17: 859-860, 2016.
132. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn M-J, Felip E, Lee J-S, Hellmann MD, Hamid O, Goldman JW, Soria J-C, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L and KEYNOTE-001 Investigators: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018-2028, 2015.
133. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HEK, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS and Hodi FS: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567, 2014.
134. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M and Wick W: Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncol 17: 1064-1075, 2015.
135. Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L and Heimberger AB: PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncol 18: 195-205, 2016.
136. Reardon DA, Sampson JH, Sahebjam S, Lim M, Baehring JM, Vlahovic G, Cloughesy TF, Strauss LC, Latek RR, Paliwal P, Harbison CT, Voloschin AD and Omuro AMP: Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. J Clin Oncol 34, 2016.
137. Reardon DA, Groot JFD, Colman H, Jordan JT, Daras M, Clarke JL, Nghiemphu PL, Gaffey SC and Peters KB: Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM). J Clin Oncol 34, 2016.
138. Sahebjam S, Johnstone PA, Forsyth PAJ, Arrington J, Vrionis FD, Etame AB, Tran ND, Dalvi PH, Kim S, Macaulay RJ, Chinnaiyan P and Yu M: Safety and antitumor activity of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab (Pembro) and bevacizumab (Bev) in patients (pts) with recurrent high grade gliomas: Preliminary results from phase I study. J Clin Oncol 34, 2016.
139. Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, Cagnano E, Limon D and Bokstein F: Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol 129: 453-460, 2016.